Journal: BMC Medicine
Article Title: Cathelicidin-related antimicrobial peptide protects against myocardial ischemia/reperfusion injury
doi: 10.1186/s12916-019-1268-y
Figure Lengend Snippet: The serum level of LL-37 is reduced in patients with myocardial infarction. a The serum level of the human cathelicidin LL-37 was measured by ELISA in patients with myocardial infarction (MI, n = 172) and normal controls ( n = 160). b The serum level of LL-37 was measured by ELISA in MI patients with cardiovascular readmission and/or death ( n = 27) compared to those without readmission and/or death ( n = 53) during the 1-year follow-up. c The serum LL-37/neutrophil ratio was determined in MI patients with cardiovascular readmission and/or death ( n = 27) compared to those without readmission and/or death ( n = 53) during the 1-year follow-up. d The receiver-operator characteristic (ROC) curve was used to assess the sensitivity and specificity of the serum LL-37/neutrophil ratio in prediction of readmission and/or death in MI patients. Data were expressed as mean ± SEM. * P < 0.05; ** P < 0.01; *** P < 0.001
Article Snippet: Supernatants from human samples were taken for measurement of the serum level of LL-37 using the human cathelicidin antimicrobial peptide (LL-37) ELISA kit (CUSABIO, CSB-EL004476HU) according to the manufacturer’s instructions.
Techniques: Enzyme-linked Immunosorbent Assay